Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy.

Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Hans-Henrik P.

J Renin Angiotensin Aldosterone Syst. 2012 Mar;13(1):118-21. doi: 10.1177/1470320311417272. Epub 2011 Aug 8.

PMID:
21824990
2.

Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators.

N Engl J Med. 2008 Jun 5;358(23):2433-46. doi: 10.1056/NEJMoa0708379.

3.

Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.

Andersen K, Weinberger MH, Constance CM, Ali MA, Jin J, Prescott MF, Keefe DL.

J Renin Angiotensin Aldosterone Syst. 2009 Sep;10(3):157-67. doi: 10.1177/1470320309342407. Epub 2009 Jul 17.

PMID:
19617271
4.

Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.

Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH.

Clin J Am Soc Nephrol. 2011 May;6(5):1025-31. doi: 10.2215/CJN.07590810. Epub 2011 Feb 24.

5.

Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.

Abe M, Suzuki H, Okada K, Maruyama N, Inoshita A, Baba S, Takashima H, Soma M.

Heart Vessels. 2013 Jul;28(4):442-52. doi: 10.1007/s00380-012-0260-7. Epub 2012 May 23.

PMID:
22618635
6.

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.

Uresin Y, Taylor AA, Kilo C, Tschöpe D, Santonastaso M, Ibram G, Fang H, Satlin A.

J Renin Angiotensin Aldosterone Syst. 2007 Dec;8(4):190-8. doi: 10.3317/jraas.2007.028.

PMID:
18205098
7.

Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.

Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH; AVOID Study Investigators.

Diabetes Care. 2010 Nov;33(11):2304-9. doi: 10.2337/dc10-0833. Epub 2010 Aug 6.

8.

Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression.

Vardeny O, Pouleur AC, Takeuchi M, Appelbaum E, Verma A, Prescott M, Smith B, Dahlof B, Solomon SD; ALLAY Investigators.

J Renin Angiotensin Aldosterone Syst. 2012 Jun;13(2):265-72. doi: 10.1177/1470320312437893. Epub 2012 Mar 13.

PMID:
22415888
9.

Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria.

Abe M, Maruyama N, Suzuki H, Fujii Y, Ito M, Yoshida Y, Okada K, Soma M.

Hypertens Res. 2012 Aug;35(8):874-81. doi: 10.1038/hr.2012.45. Epub 2012 May 17.

PMID:
22592665
10.

Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.

Dietz R, Dechend R, Yu CM, Bheda M, Ford J, Prescott MF, Keefe DL.

J Renin Angiotensin Aldosterone Syst. 2008 Sep;9(3):163-75. doi: 10.1177/1470320308096411.

PMID:
18957387
11.
12.

Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria.

Fogari R, Mugellini A, Zoppi A, Preti P, Maffioli P, Perrone T, Derosa G.

Expert Opin Pharmacother. 2013 Mar;14(4):371-84. doi: 10.1517/14656566.2013.772981. Epub 2013 Feb 17.

PMID:
23414196
13.

Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study.

Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH.

J Renin Angiotensin Aldosterone Syst. 2012 Jun;13(2):250-3. doi: 10.1177/1470320312437068. Epub 2012 Feb 16.

PMID:
22345094
14.

Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.

Drummond W, Sirenko YM, Ramos E, Baek I, Keefe DL.

Am J Cardiovasc Drugs. 2011 Oct 1;11(5):327-33. doi: 10.2165/11591970-000000000-00000.

PMID:
21846154
15.

[Advantages and limitations of renin inhibition with aliskiren].

Azizi M, Frank M, Steichen O, Blanchard A.

Ann Pharm Fr. 2011 May;69(3):142-50. doi: 10.1016/j.pharma.2011.02.002. Epub 2011 Apr 21. Review. French.

PMID:
21570538
16.

Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension.

Nussberger J, Gradman AH, Schmieder RE, Lins RL, Chiang Y, Prescott MF.

Int J Clin Pract. 2007 Sep;61(9):1461-8. Epub 2007 Jun 22.

PMID:
17590217
17.

[Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].

Horký K.

Vnitr Lek. 2010 Feb;56(2):120-6. Review. Czech.

PMID:
20329582
18.

Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial.

Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, Danser AH, Boomsma F, Frandsen E, Parving HH.

Diabetologia. 2010 Aug;53(8):1576-80. doi: 10.1007/s00125-010-1789-6. Epub 2010 May 18.

PMID:
20480132
19.

[Renin inhibition and the kidney].

Ecder T.

Turk Kardiyol Dern Ars. 2009 Oct;37 Suppl 7:28-31. Turkish.

20.

Direct renin inhibition: an update.

Pinto R, Gradman AH.

Curr Hypertens Rep. 2009 Dec;11(6):456-62. Review.

PMID:
19895758

Supplemental Content

Support Center